Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma

• Krithika Kodumudi,
• Brian J Czerniecki,
• Doris Wiener,
• Ganesan Ramamoorthi,
• Colin Snyder,
• Payal Grover,
• Hongtao Zhang,
• Mark I Greene,
• Amrita Basu,
• Corey Gallen,
• Ricardo L B Costa,
• Hyo S Han,
• Gary Koski

Affiliations

Krithika Kodumudi

Aff1 grid.170693.a000000012353285XMoffitt Cancer Center Tampa FL USA

Brian J Czerniecki

Aff1 grid.25879.310000000419368972University of Pennsylvania Perelman School of Medicine PA USA

Doris Wiener

Aff186 Lion Biotechnologies, Inc. Tampa FL USA

Ganesan Ramamoorthi

Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA

Colin Snyder

Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA

Payal Grover

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Hongtao Zhang

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Mark I Greene

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Amrita Basu

Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA

Corey Gallen

Clinical Science & Immunology Program, Moffitt Cancer Center, Tampa, Florida, USA

Ricardo L B Costa

Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA

Hyo S Han

Department of Breast Oncology, Moffitt Cancer Center, Tampa, Florida, USA

Gary Koski

Biological Sciences, Kent State University, Kent, Ohio, USA